Step 1: Choose the right case
Yes, when using compliant platforms with registered Irish doctors
Early evidence suggests several profiles: People with concurrent obesity or type 2 diabetes who already have medical indications for semaglutide Individuals who haven't responded adequately to traditional medications for alcoholism, like naltrexone or acamprosate Those struggling with heavy drinking, rather than severe physiological dependence, require medical detoxification Patients seeking to reduce consumption rather than achieve complete abstinence initially A case series of six patients receiving semaglutide for weight loss showed a marked reduction in Alcohol Use Disorder Identification Test (AUDIT) scores for all participants, demonstrating real-world effectiveness outside controlled trial settings
But in the long term, the true gold standard for morbid obesity will ultimately be determined by durability, metabolic outcomes, safety, affordability, and sustained patient success
Lemmes GLP-1 Daily claims to naturally support appetite, metabolism, and fat reduction